Literature DB >> 29282534

Computerized cognitive training in prostate cancer patients on androgen deprivation therapy: a pilot study.

Lisa M Wu1, Ali Amidi2, Molly L Tanenbaum3, Gary Winkel4, Wayne A Gordon5, Simon J Hall6, Katrin Bovbjerg7, Michael A Diefenbach6.   

Abstract

PURPOSE: Prostate cancer patients who have undergone androgen deprivation therapy (ADT) may experience cognitive impairment, yet there is an unmet need for nonpharmacological interventions to address cognitive impairment in this population. This study examines the feasibility, acceptability, and preliminary efficacy of a home-based computerized cognitive training (CCT) program to treat cancer-related cognitive impairment.
METHODS: Sixty men who had received ≥ 3 months of ADT were screened for at least mild cognitive or neurobehavioral impairment and randomized to 8 weeks of CCT or usual care. Follow-up assessments occurred immediately post-intervention or equivalent (T2) and 8 weeks later (T3). The acceptability of CCT was also assessed.
RESULTS: Feasibility:A priori feasibility thresholds were partially met (i.e., randomization rate > 50%, retention rate > 70% excluding CCT drop-outs, but < 70% for intent-to-treat). Acceptability: Participants were mostly satisfied with CCT and found it somewhat enjoyable, though barriers to uptake existed. Preliminary efficacy: Linear mixed models indicated significant time by group effects favorable to CCT in reaction time (p = .01), but unfavorable to CCT in verbal and visual memory (ps < .05). Memory was temporarily suppressed in the CCT group at T2, but normalized by T3. There was no effect of CCT on self-reported cognitive functioning, neurobehavioral functioning, nor quality of life.
CONCLUSIONS: This study provides tentative support for the feasibility and acceptability of CCT to treat mild cognitive impairment in ADT patients. CCT had a beneficial effect on reaction time, but temporarily suppressed memory. CCT's benefits may be limited to a narrow area of functioning. Larger-scale studies are needed.

Entities:  

Keywords:  Antiandrogens; Cancer-related cognitive impairment; Cognition; Computers; Hormone therapy; Oncology

Mesh:

Substances:

Year:  2017        PMID: 29282534      PMCID: PMC5924582          DOI: 10.1007/s00520-017-4026-8

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  34 in total

1.  Reliability and validity of a computerized neurocognitive test battery, CNS Vital Signs.

Authors:  C Thomas Gualtieri; Lynda G Johnson
Journal:  Arch Clin Neuropsychol       Date:  2006-10-02       Impact factor: 2.813

Review 2.  The processing-speed theory of adult age differences in cognition.

Authors:  T A Salthouse
Journal:  Psychol Rev       Date:  1996-07       Impact factor: 8.934

3.  Effects of long-term androgen deprivation therapy on cognitive function over 36 months in men with prostate cancer.

Authors:  Shabbir M H Alibhai; Narhari Timilshina; Sarah Duff-Canning; Henriette Breunis; Ian F Tannock; Gary Naglie; Neil E Fleshner; Murray D Krahn; Padraig Warde; Shireen Marzouk; George A Tomlinson
Journal:  Cancer       Date:  2016-09-01       Impact factor: 6.860

Review 4.  Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience.

Authors:  M Han; A W Partin; C R Pound; J I Epstein; P C Walsh
Journal:  Urol Clin North Am       Date:  2001-08       Impact factor: 2.241

5.  Effects of cognitive training interventions with older adults: a randomized controlled trial.

Authors:  Karlene Ball; Daniel B Berch; Karin F Helmers; Jared B Jobe; Mary D Leveck; Michael Marsiske; John N Morris; George W Rebok; David M Smith; Sharon L Tennstedt; Frederick W Unverzagt; Sherry L Willis
Journal:  JAMA       Date:  2002-11-13       Impact factor: 56.272

6.  Evaluation of a Web-Based Cognitive Rehabilitation Program in Cancer Survivors Reporting Cognitive Symptoms After Chemotherapy.

Authors:  Victoria J Bray; Haryana M Dhillon; Melanie L Bell; Michael Kabourakis; Mallorie H Fiero; Desmond Yip; Frances Boyle; Melanie A Price; Janette L Vardy
Journal:  J Clin Oncol       Date:  2016-10-28       Impact factor: 44.544

7.  Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument.

Authors:  P Esper; F Mo; G Chodak; M Sinner; D Cella; K J Pienta
Journal:  Urology       Date:  1997-12       Impact factor: 2.649

8.  Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial.

Authors:  Daniel A Galvão; Dennis R Taaffe; Nigel Spry; David Joseph; Robert U Newton
Journal:  J Clin Oncol       Date:  2009-11-30       Impact factor: 44.544

9.  Implementing an expressive writing study in a cancer clinic.

Authors:  Nancy P Morgan; Kristi D Graves; Elizabeth A Poggi; Bruce D Cheson
Journal:  Oncologist       Date:  2008-02

10.  An overview of randomization techniques: An unbiased assessment of outcome in clinical research.

Authors:  Kp Suresh
Journal:  J Hum Reprod Sci       Date:  2011-01
View more
  8 in total

Review 1.  The increasing value of eHealth in the delivery of patient-centred cancer care.

Authors:  Frank J Penedo; Laura B Oswald; Joshua P Kronenfeld; Sofia F Garcia; David Cella; Betina Yanez
Journal:  Lancet Oncol       Date:  2020-05       Impact factor: 41.316

Review 2.  Androgen Deprivation Therapy and Cognitive Function in Prostate Cancer.

Authors:  Jonathan Kluger; Alicia Roy; Herta H Chao
Journal:  Curr Oncol Rep       Date:  2020-02-11       Impact factor: 5.075

Review 3.  Cognitive Rehabilitation for Cognitive Dysfunction after Cancer and Cancer Treatment: Implications for Nursing Practice.

Authors:  Diane Von Ah; Adele Crouch
Journal:  Semin Oncol Nurs       Date:  2020-01-17       Impact factor: 2.315

Review 4.  Cancer-related cognitive impairment in patients with non-central nervous system malignancies: an overview for oncology providers from the MASCC Neurological Complications Study Group.

Authors:  Samantha J Mayo; Maryam Lustberg; Haryana M Dhillon; Zev M Nakamura; Deborah H Allen; Diane Von Ah; Michelle C Janelsins; Alexandre Chan; Karin Olson; Chia Jie Tan; Yi Long Toh; Jeong Oh; Lisa Grech; Yin Ting Cheung; Ishwaria Mohan Subbiah; Duska Petranovic; James D'Olimpio; Margherita Gobbo; Susanne Koeppen; Charles L Loprinzi; Linda Pang; Shivani Shinde; Olanipekun Ntukidem; Katherine B Peters
Journal:  Support Care Cancer       Date:  2020-11-24       Impact factor: 3.603

5.  Measuring Self-Reported Cancer-Related Cognitive Impairment: Recommendations from the Cancer Neuroscience Initiative Working Group.

Authors:  Ashley M Henneghan; Kathleen Van Dyk; Tara Kaufmann; Rebecca Harrison; Christopher Gibbons; Cobi Heijnen; Shelli R Kesler
Journal:  J Natl Cancer Inst       Date:  2021-02-26       Impact factor: 13.506

Review 6.  Androgen Regulation of the Mesocorticolimbic System and Executive Function.

Authors:  Daniel J Tobiansky; Kathryn G Wallin-Miller; Stan B Floresco; Ruth I Wood; Kiran K Soma
Journal:  Front Endocrinol (Lausanne)       Date:  2018-06-05       Impact factor: 5.555

7.  Computerized cognitive training in post-treatment hematological cancer survivors: a feasibility study.

Authors:  Samantha J Mayo; Sean B Rourke; Eshetu G Atenafu; Rita Vitorino; Christine Chen; John Kuruvilla
Journal:  Pilot Feasibility Stud       Date:  2021-01-30

Review 8.  Effect of androgen deprivation therapy on cognitive functioning in men with prostate cancer: A systematic review.

Authors:  Cornelie D Andela; Rafil Matte; Ingrid M Jazet; Willemijn Cg Zonneveld; Jan W Schoones; A Edo Meinders
Journal:  Int J Urol       Date:  2021-06-14       Impact factor: 2.896

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.